Literature DB >> 16030401

[Preoperative diagnosis and management for hilar cholangiocarcinoma].

Young Joo Lee1.   

Abstract

Liver resection with extrahepatic bile duct resection, wide lymph node dissection and caudate lobectomy has become the standard treatment for patients with hilar cholangiocarcinoma. More extended surgery, such as hepatopancreatoduodenectomy, combined portal vein and liver resection, has been accepted for treatment. Such aggressive resection could only offers better chance of long-term survival, but postoperative morbidity and mortality is still high. Various preoperative diagnostic and management modalities including PTBD, PTCS, angiography, MR angiography, MR cholangiography, DCT, CT angiography and PTPE are very important for optimal treatment and reduced mortality. It is recommended that surgeons, physicians, endoscopists, and radiologists, including interventional radiologists should perform the diagnosis and preoperative management of patients with hilar cholangiocarcinoma in a concerted way.

Entities:  

Mesh:

Year:  2005        PMID: 16030401

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  3 in total

1.  Preoperative evaluation with T-staging system for hilar cholangiocarcinoma.

Authors:  Ru-Fu Chen; Zhi-Hua Li; Jia-Jia Zhou; Jie Wang; Ji-Sheng Chen; Qing Lin; Qi-Bing Tang; Ning-Fu Peng; Zhi-Peng Jiang; Quan-Bo Zhou
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

2.  The role of percutaneous transhepatic cholangioscopy in patients with hilar strictures.

Authors:  Ju Young Jung; Sung Koo Lee; Hyoung-Chul Oh; Tae-Yoon Lee; Seung Hyun Kwon; Sang Soo Lee; Dong Wan Seo; Myung-Hwan Kim
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

Review 3.  Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Hongchen Zhang; Jian Zhu; Fayong Ke; Mingzhe Weng; Xiangsong Wu; Maolan Li; Zhiwei Quan; Yingbin Liu; Yong Zhang; Wei Gong
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.